Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics to treat energetic failure, an underlying driver of many neurological diseases. The Company’s lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neurorepair and improve neuroprotection. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses.
Location: United States, Utah, Salt Lake City
Employees: 51-200
Total raised: $42.5M
Founded date: 2013
Investors 2
| Date | Name | Website |
| - | SV Investm... | svinvest.c... |
| - | SymBiosis | symbiosis.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.08.2020 | Series D | $42.5M | - |
Mentions in press and media 9
| Date | Title | Description |
| 27.05.2024 | Blood Test Identifies Immune Response in Multiple Sclerosis Patients, Paves Way for New Treatments | By Quincy Jon Published May 27, 2024 1:35PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard Share on Pocket Researchers have created a blood test to detect multiple sclerosis (MS) patients' immuno... |
| 13.03.2024 | Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights | - |
| 07.03.2024 | Clene to Present at the 36th Annual ROTH Conference | - |
| 04.10.2022 | ROTH Capital Partners to Host Inaugural Healthcare Opportunities Conference on October 6th at the Yale Club in New York City | Event to feature company presentations and one-on-one meetings between institutional investors and senior management from select Healthcare companies in Biotechnology, Pharmaceuticals, Medical Technologies, Oncology and Mental Health Therap... |
| 24.05.2021 | CLENE INC. Clene : Announces Plan to Expand its Manufacturing Capacity of CNM-Au8, Closing of Up to $30 Million Debt Facility, and Financing Agreements for $9.25 Million At-the-Market Private Placeme... | Clene Announces Plan to Expand its Manufacturing Capacity of CNM-Au8, Closing of Up to $30 Million Debt Facility, and Financing Agreements for $9.25 Million At-the-Market Private Placement SALT LAKE CITY, UT, May 24, 2021 -- Clene Inc. (NAS... |
| 24.05.2021 | CLENE INC. Clene : Announces Plan to Expand its Manufacturing Capacity of CNM-Au8, Closing of Up to $30 Million Debt Facility, and Financing Agreements for $9.25 Million At-the-Market Private Placeme... | SALT LAKE CITY, May 24, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatmen... |
| 18.11.2020 | Maryland is eyeing these 20 startups for future success | Tuesday was National Entrepreneur’s Day, and Gov. Larry Hogan of Maryland used the occasion to announce his list of 20 promising startups across the state. The Maryland Future 20, released by the Maryland Department of Commerce, aims to hig... |
| 28.08.2020 | Clene Nanomedicine Raises $42.5M in Series D Funding | Clene Nanomedicine, Inc., a Salt Lake City, UT-based clinical-stage biopharmaceutical company focused on the development of nanocatalysts for the treatment of bioenergetic failure associated with neurodegenerative diseases, raised $42.5m in... |
| 26.08.2020 | Clene Nanomedicine Raises $42.5M Series D Financing | Clene Nanomedicine, Inc., a Salt Lake City, UT-based clinical-stage biopharmaceutical company, secured $42.5m in Series D financing. The round was led by SymBiosis II, LLC, a biotech-focused investment vehicle. Participants in the round inc... |